Paul A. Aristoff

2.8k citations

49 papers · 2.1k indexed · h-index 23

Co-authors: Paul D. Johnson Thomas H. Pillow John A. Flygare Fritz Reusser Donna L. Romero Allen W. Harrison Paul D. Kirchhoff George A. Garcia
Topics: HIV/AIDS drug development and treatment (12 papers)HIV Research and Treatment (8 papers)Cancer therapeutics and mechanisms (7 papers)
Cited by: Virology Infectious Diseases Organic Chemistry
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society Journal of Biological Chemistry
Partner nations: United States Switzerland New Zealand

In The Last Decade

Paul A. Aristoff

47 papers receiving 2.0k citations

Peers

Countries citing papers authored by Paul A. Aristoff

Since Specialization

Citations

This map shows the geographic impact of Paul A. Aristoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul A. Aristoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul A. Aristoff more than expected).

Fields of papers citing papers by Paul A. Aristoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul A. Aristoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul A. Aristoff. The network helps show where Paul A. Aristoff may publish in the future.

Co-authorship network of co-authors of Paul A. Aristoff

This figure shows the co-authorship network connecting the top 25 collaborators of Paul A. Aristoff. A scholar is included among the top collaborators of Paul A. Aristoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul A. Aristoff. Paul A. Aristoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure–Activity Relationship of Flavin Analogues That Target the Flavin Mononucleotide Riboswitch 2018 ·ACS Chemical Biology ·Quentin Vicens,Estefanía Mondragón,F.E. Reyes,Philip Coish,Paul A. Aristoff,Judd Berman,Harpreet Kaur,(unknown),(unknown),(unknown),Robert C. Gadwood,Heinrich J. Schostarez,R.K. Suto,Ken Blount,Robert Batey	50
2	Inhibition of mycobacterial alanine racemase activity and growth by thiadiazolidinones 2013 ·Biochemical Pharmacology ·Yashang Lee,(unknown),(unknown),Michelle S DeStefano,Pier F. Cirillo,Oluwatoyin A. Asojo,(unknown),Michel Ledizet,Michael H. Cynamon,Paul A. Aristoff,Raymond A. Koski,(unknown),Karen Anthony	18
3	A Novel Allosteric Inhibitor of Macrophage Migration Inhibitory Factor (MIF) 2012 ·Journal of Biological Chemistry ·Fengwei Bai,Oluwatoyin A. Asojo,Pier F. Cirillo,(unknown),Michel Ledizet,Paul A. Aristoff,Lin Leng,Raymond A. Koski,Thomas Powell,Richard Bucala,Karen Anthony	61
4	Antibody‐Drug Conjugates for the Treatment of Cancer 2012 ·Chemical Biology & Drug Design ·John A. Flygare,Thomas H. Pillow,Paul A. Aristoff	178
5	Thiadiazolidinones: A new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant Staphylococcus aureus 2011 ·Biochemical Pharmacology ·(unknown),(unknown),Adriana E. Rosato,Oriana A. Perez,Pier F. Cirillo,(unknown),Michel Ledizet,Michael H. Cynamon,Paul A. Aristoff,Raymond A. Koski,(unknown),Karen Anthony	14
6	New Classes of Alanine Racemase Inhibitors Identified by High-Throughput Screening Show Antimicrobial Activity against Mycobacterium tuberculosis 2011 ·PLoS ONE ·Karen Anthony,Ulrich Strych,(unknown),(unknown),Oriana A. Perez,Kurt L. Krause,Michael H. Cynamon,Paul A. Aristoff,Raymond A. Koski	29
7	Rifamycins – Obstacles and opportunities 2010 ·Tuberculosis ·Paul A. Aristoff,George A. Garcia,Paul D. Kirchhoff,Hollis D. Showalter	140
8	Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate 2006 ·Kluwer Academic Publishers eBooks ·Wade J. Adams,Paul A. Aristoff,Richard K. Jensen,W. Morozowich,Donna L. Romero,(unknown),W. Gary Tarpley,Richard C. Thomas	10
9	Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials 2003 ·Bioorganic & Medicinal Chemistry Letters ·Paul D. Johnson,Paul A. Aristoff,Gary E. Zurenko,Ronda D. Schaadt,Betty H. Yagi,Charles W. Ford,Judith C. Hamel,Douglas Stapert,(unknown)	30
10	The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase 1996 ·Biochemical Pharmacology ·Irene W. Althaus,Kuo‐Chen Chou,(unknown),(unknown),Martin R. Deibel,Ferenc J. Kézdy,Lionel Resnick,Mariano Busso,Antero G. So,Kathleen M. Downey,Donna L. Romero,Richard C. Thomas,Paul A. Aristoff,W. Gary Tarpley,Fritz Reusser	66
11	Structure-Based Design of HIV Protease Inhibitors: 5,6-Dihydro-4-hydroxy-2-pyrones as Effective, Nonpeptidic Inhibitors 1996 ·Journal of Medicinal Chemistry ·Suvit Thaisrivongs,Donna L. Romero,Rubén Tommasi,Musiri N. Janakiraman,Joseph W. Strohbach,Steve R. Turner,Carolyn Biles,(unknown),Paul D. Johnson,Paul A. Aristoff,Paul K. Tomich,Janet C. Lynn,Miao-Miao Horng,Kong-Teck Chong,Roger R. Hinshaw,W. Jeffrey Howe,B.C. Finzel,Keith David Watenpaugh	65
12	Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E 1994 ·Biochemical Pharmacology ·Irene W. Althaus,James J. Chou,Andrea J. Gonzales,Martin R. Deibel,(unknown),Ferenc J. Kézdy,Donna L. Romero,Richard C. Thomas,Paul A. Aristoff,W. Gary Tarpley,Fritz Reusser	57
13	Steady-state kinetic studies with the polysulfonate U-9843, an HIV reverse transcriptase inhibitor 1994 ·Cellular and Molecular Life Sciences ·Irene W. Althaus,James J. Chou,Andrea J. Gonzales,(unknown),Martin R. Deibel,K.-C. Chou,Ferenc J. Kézdy,Donna L. Romero,R.C. Thomas,Paul A. Aristoff,W. Gary Tarpley,Fritz Reusser	40
14	Synthesis and biochemical evaluation of the CBI-PDE-I-dimer, a benzannelated analog of (+)-CC-1065 that also produces delayed toxicity in mice 1993 ·Journal of Medicinal Chemistry ·Paul A. Aristoff,Paul D. Johnson,Daekyu Sun,(unknown)	33
15	Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. 1993 ·Journal of Biological Chemistry ·Irene W. Althaus,James J. Chou,Andrea J. Gonzales,Martin R. Deibel,Kuo‐Chen Chou,Ferenc J. Kézdy,Mariana Romero,Paul A. Aristoff,W. Gary Tarpley,Fritz Reusser	150
16	Sequence-selective guanine reactivity by duocarmycin A 1993 ·Chemical Research in Toxicology ·Mark A. Mitchell,(unknown),Paul A. Aristoff,Paul D. Johnson,Thomas P. Dooley	5
17	ChemInform Abstract: Synthesis of CBI‐PDE‐I‐Dimer, the Benzannelated Analogue of CC‐1065. 1993 ·ChemInform ·Paul A. Aristoff,Paul D. Johnson	3
18	Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843 1992 ·Cellular and Molecular Life Sciences ·Irene W. Althaus,(unknown),Andrea J. Gonzales,Martin R. Deibel,Satish Kumar Sharma,Ferenc J. Kézdy,Lionel Resnick,Mariano Busso,Paul A. Aristoff,Fritz Reusser	10
19	Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. 1991 ·Proceedings of the National Academy of Sciences ·Donna L. Romero,M. Busso,(unknown),Fritz Reusser,Julie R. Palmer,Susan M. Poppe,Paul A. Aristoff,Kathleen M. Downey,Antero G. So,Lionel Resnick	224
20	ChemInform Abstract: IMPROVED METHOD FOR THE CONVERSION OF ENOL LACTONES TO CYCLIC α,β‐UNSATURATED KETONES 1985 ·Chemischer Informationsdienst ·Paul A. Aristoff	1

About Paul A. Aristoff

Paul A. Aristoff is a scholar working on Virology, Toxicology and Infectious Diseases, having authored 49 papers that have together received 2.1k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (8 papers) and Cancer therapeutics and mechanisms (7 papers). The work is most often cited by research in Virology (340 citations), Infectious Diseases (546 citations) and Organic Chemistry (717 citations). Paul A. Aristoff has collaborated with scholars based in United States, Switzerland and New Zealand. Frequent co-authors include Paul D. Johnson, Thomas H. Pillow, John A. Flygare, Fritz Reusser, Donna L. Romero, Allen W. Harrison, Paul D. Kirchhoff, George A. Garcia, Hollis D. Showalter and W. Gary Tarpley. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact